Quest Diagnostics reported results for the quarter ended 2026 with revenue of $3.04B, net income of $320M and diluted EPS of $2.84, each up versus the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$3.04B$2.76B10.2% | Net income²$320M$282M13.5% | Diluted EPS³$2.84$2.4715% |
¹ Reported as “Net revenues”. ² Reported as “Net income attributable to Quest Diagnostics”. ³ Reported as “Diluted earnings per share attributable to Quest Diagnostics’ common stockholders”.
Business Highlights
- Revenue growth was driven by approximately 13% requisition volume growth and new partnerships that shifted channel mix.
- New partnerships with Corewell Health and Fresenius dialysis clinics contributed roughly 8–9% of organic volume growth.
- The Invigorate productivity program targets about 3% annual cost savings through automation, AI and process improvements across labs and services.
- Closed a Michigan joint venture with Corewell (consolidated, 51% ownership) and is building a new laboratory expected to be operational in 2027.
- Nationwide expansion of patient service centers, mobile phlebotomy and consulting medical staff supported increased testing demand.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.